These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 24860099)

  • 1. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target.
    Holmes BB; Diamond MI
    J Biol Chem; 2014 Jul; 289(29):19855-61. PubMed ID: 24860099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau
    Stopschinski BE; Holmes BB; Miller GM; Manon VA; Vaquer-Alicea J; Prueitt WL; Hsieh-Wilson LC; Diamond MI
    J Biol Chem; 2018 Jul; 293(27):10826-10840. PubMed ID: 29752409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prions: generation and spread versus neurotoxicity.
    Halliday M; Radford H; Mallucci GR
    J Biol Chem; 2014 Jul; 289(29):19862-8. PubMed ID: 24860100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of proteins in neurodegenerative disease].
    Szwed A; Miłowska K
    Postepy Hig Med Dosw (Online); 2012 Apr; 66():187-95. PubMed ID: 22706103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau Prion-Like Propagation: State of the Art and Current Challenges.
    Dujardin S; Hyman BT
    Adv Exp Med Biol; 2019; 1184():305-325. PubMed ID: 32096046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sulfation code for propagation of neurodegeneration.
    Yamada M; Hamaguchi T
    J Biol Chem; 2018 Jul; 293(27):10841-10842. PubMed ID: 29980653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Travels with tau prions.
    Diamond MI
    Cytoskeleton (Hoboken); 2024 Jan; 81(1):83-88. PubMed ID: 37950616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse models for studying the formation and propagation of prions.
    Watts JC; Prusiner SB
    J Biol Chem; 2014 Jul; 289(29):19841-9. PubMed ID: 24860095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodegeneration. Could they all be prion diseases?
    Miller G
    Science; 2009 Dec; 326(5958):1337-9. PubMed ID: 19965731
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.
    Funk KE; Mirbaha H; Jiang H; Holtzman DM; Diamond MI
    J Biol Chem; 2015 Aug; 290(35):21652-62. PubMed ID: 26126828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of yeast to studying amyloid and prion diseases.
    Chernoff YO; Grizel AV; Rubel AA; Zelinsky AA; Chandramowlishwaran P; Chernova TA
    Adv Genet; 2020; 105():293-380. PubMed ID: 32560789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
    Hasegawa M
    Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease.
    Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K
    Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds.
    Holmes BB; DeVos SL; Kfoury N; Li M; Jacks R; Yanamandra K; Ouidja MO; Brodsky FM; Marasa J; Bagchi DP; Kotzbauer PT; Miller TM; Papy-Garcia D; Diamond MI
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):E3138-47. PubMed ID: 23898162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.
    Jucker M; Walker LC
    Nature; 2013 Sep; 501(7465):45-51. PubMed ID: 24005412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of crowded physiological environments in prion and prion-like protein aggregation.
    Ma Q; Hu JY; Chen J; Liang Y
    Int J Mol Sci; 2013 Oct; 14(11):21339-52. PubMed ID: 24284393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases.
    Díaz-Nido J; Wandosell F; Avila J
    Peptides; 2002 Jul; 23(7):1323-32. PubMed ID: 12128089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structural line between prion and "prion-like": Insights from prion protein and tau.
    Glynn C; Rodriguez JA; Hyman BT
    Curr Opin Neurobiol; 2024 Jun; 86():102857. PubMed ID: 38489865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is tau ready for admission to the prion club?
    Hall GF; Patuto BA
    Prion; 2012 Jul; 6(3):223-33. PubMed ID: 22561167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies.
    Goedert M; Falcon B; Clavaguera F; Tolnay M
    Curr Neurol Neurosci Rep; 2014 Nov; 14(11):495. PubMed ID: 25218483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.